Related Experiment Video
Updated: Jun 8, 2026
07:30
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
[Incretin related drugs]
Yusuke Hada1, Toshimasa Yamauchi, Takashi Kadowaki
1Department of Metabolic Disease, The University of Tokyo Hospital.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|October 20, 2010
Summary
Incretin hormones like GLP-1 and GIP regulate blood glucose. New incretin-based drugs, including GLP-1 analogs and DPP-4 inhibitors, offer a promising strategy for type 2 diabetes treatment with a low risk of hypoglycemia.
Area of Science:
- Endocrinology and Metabolism
- Pharmacology
Context:
- Incretins (GIP and GLP-1) are crucial hormones for glucose homeostasis.
- Rapid degradation of incretins by DPP-4 limits their therapeutic potential.
- Type 2 diabetes management requires effective glucose-lowering strategies.
Purpose:
- To review the role of incretins in glucose regulation.
- To discuss the development and mechanisms of novel incretin-related drugs.
- To highlight the therapeutic potential of these agents in type 2 diabetes.
Summary:
- Incretins, secreted by K and L cells, lower blood glucose but are quickly degraded by DPP-4.
- GLP-1 analogs are engineered for DPP-4 resistance, while DPP-4 inhibitors block enzyme activity.
- Both drug classes effectively lower glucose when levels are high, minimizing hypoglycemia risk.
Impact:
- Incretin-based therapies represent a significant advancement in type 2 diabetes treatment.
- These drugs offer a new therapeutic avenue with a favorable safety profile regarding hypoglycemia.
- Further research and clinical application are expected to improve patient outcomes in type 2 diabetes.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:17Oral Hypoglycemic Agents: Sulfonylureas
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...